Docetaxel
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Docetaxel and local guidelines before prescribing.
Taxane cytotoxic
Mechanism
Taxane stabilising microtubules.
Uses
Breast, prostate, lung, gastric and head and neck cancers.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Neutropenia, fluid retention, neuropathy, alopecia, hypersensitivity.
Interactions
CYP3A4 inhibitors.
Contraindications and cautions
Severe neutropenia, hepatic impairment
Monitoring
FBC, LFT
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Contraindicated in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Dexamethasone premedication; FBC before each cycle.
More from the textbook: uses, cautions and other points
- Taxanes | Paclitaxel , docetaxel - peripheral neuropathy , hypersensitivity reactions (premedication), neutropenia, fluid retention (docetaxel), nail changes
Oncology: Principles - Plus a newer hormonal drug (abiraterone, enzalutamide, apalutamide or darolutamide), with or without docetaxel .
Oncology: Urology and Genital cancers - Docetaxel / cabazitaxel | Prostate cancer chemotherapy; neutropenia, neuropathy.
Oncology: Urology and Genital cancers
Where it is discussed in the book
- Oncology: Principles (1 mention)
- Oncology: Urology and Genital cancers (2 mentions)